Interleukin-6 receptor subunit alpha (soluble form) (sIL-6R)

The soluble form of the Interleukin-6 receptor alpha chain (sIL-6R) is a circulating protein generated through the limited proteolysis of the membrane-bound receptor or via alternative splicing of IL6R mRNA (UniProt: P08887). Unlike most soluble receptors that act as decoys, sIL-6R functions as an agonist by forming a complex with IL-6 that can activate the ubiquitously expressed signal-transducing subunit gp130, a process known as "trans-signaling" (PMID: 29063004). This mechanism allows IL-6 to affect a much broader range of cell types than those expressing the membrane-bound receptor, contributing significantly to the pathogenesis of chronic inflammatory diseases, such as rheumatoid arthritis and Crohn's disease (PubMed: 32433880). Therapeutic agents like tocilizumab and sarilumab target both the soluble and membrane-bound forms of the receptor to inhibit IL-6-mediated signaling and reduce systemic inflammation (StatPearls: Tocilizumab). Additionally, novel inhibitors like olamkicept are being developed to specifically target the soluble receptor complex to minimize side effects associated with global IL-6 blockade (PMID: 33503444). Because gp130 is expressed on nearly all cells, the sIL-6R/IL-6 complex acts as a potent systemic driver of inflammation, making it a critical target in managing cytokine release syndrome and severe respiratory distress in viral infections.

Other names

Soluble interleukin-6 receptorsIL-6RCD126Soluble CD126IL-6R-alphaIL6RA

Monoclonal antibodies bind to both soluble and membrane-bound forms of the IL-6 receptor, preventing IL-6 from binding and initiating the JAK/STAT signaling pathway (StatPearls: Tocilizumab). Specific inhibitors like olamkicept selectively target the sIL-6R/IL-6 complex to block trans-signaling while sparing classic signaling (PMID: 33503444).